List view / Grid view
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
Explore the step-by-step scientific workflow behind drug discovery, from formulating hypotheses to analysing data, ensuring accurate and reliable results.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
So-called undruggable pharmaceutical targets could be tackled with intermediate sized drugs such as macrocycles, combining the advantages of small molecules and biologics. The preparation of very large libraries of chemically synthesised intermediate-sized molecules is now in reach with a new technology developed at ETH Zurich. In this article, Dr Michelle…
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
